T HE enzyme, glutamic oxalacetic transamMase (GO-T), has been found in all human and animal sera that have been tested. This traiisamniiase has been found in high concentration in heart muscle, skeletal muscle, brain, liver and kidney in decreasing order." 2, oxalacetic transaminase (SGO-T) appear to be roughly proportional to the amount of myocardial necrosis. Striking elevations of the serum level follow acute or chronic liver damages 11 and lesser rises occur after acute renal or skeletal muscle damage. '2' 3 The serum level of glutamic oxalacetic transaminase has not been found to be elevated in a large group of patients with infectious, neoplastic, allergic and degenerative disease states unless evidence of acute damage to the liver, heart or skeletal muscle was present.
The observation that myocardial necrosis could be detected by measurement of the changes in the serum concentrations of glutamic oxalacetic transaminase led us to study alterations of enzyme concentration in different groups of rheumatic patients. Assay of the enzyme was performed by a simple rapid spectrophotometric method. 6 The test for C-reactive protein was lerformled by the capillary precipitation method as described by Anderson and MIcCarty,'5 employing an antiserum prepared by injecting rabbits with purified, crystalline C-reactive protein of human origin. The erythrocyte sedimentation rate (ESR) was determined by the Wintrobe method and coirected for variations in hematocrit according to standard tables.
Liver function tests, performe(l in most patients exhibiting rises in serum levels of transaminase included sulfobromophthalein retention (BSP), serum alkaline phosphatase, cephalin flocculation and serum bilirubinldeterminations.
Measturement of Enzyme (SGO-T)
The spectrophotometriic method of assay wvas used6 ( fig. 1 Group II includes patients with rheumatic fever andl previously known rheumatic heart disease. The evidence for active cardiac involvement was consi(lered to be equivocal in the absence of the appearance of new cardiac manifestations during the observed attack, despite laboratory evidence of continuing inflammation.
Group III contains two categories of patients with rheumatic fever, but with no known cardiac involvement; (1) polyarthritis, (2) chorea or erythema marginatum.
Group IV is composed of patients with inactive rheumatic fever but with known carditis in the past. This group is further(divided into children convalescing from a recent attack of active carditis and .a(lults who have recovered from rheumatic fever years previously an(l at present show inactive rheumatic heart disease.
The period of convalescence is (lated from the (lay suppressive antirheumatic therapy was with-(liawn if no laboratory or clinical evidence of an exacerbation of rheumatic activity supervened during the following two months.18
Group V contains patients with inactive rheumatic fever who developed virus l)neumonila.
Group VI is composed of 16 patients with active rheumatoid arthritis (no evidence of cardiac involvement) and osteoarthritis..
The behavior of the transaminase in the untreated rheumatic could not be studied adequately because so many of the patients showed severe cardiac involvement and it was believed necessary to administer steroids or salicylates in an attempt to suppress inflammation.
RESULTS
The 80 patients studied are listed in The serum glutamic oxalacetic traiisamiinase showed striking alterations. It was 140 units on admission at a time when theie was moderate heart failure, signs of mild liver dysfunction and before pulmonariy emboli had occurir-ed. Pulmonai-y emboli occui-ed on June 12 and 16. A rise of se-um transaminase to 2,000 units (the highest recorded in this series) occurred on June 18. The bili-ubin subsequentlyirose and heait failure became moie severie. Despite intractable heart failure, another pulmonaiy embolus and the appearance of a pericardial friction iub, the serum transaminase level gradually fell to no-mal before the patient died.
At autopsy, the heait weighed 735 Gm., an extensive fibrinous pericaiditis was seen, all chambers were dilated and their walls hypeit-ophied, and the imitral, aortic and tricuspid valves showed typical nonbacterial rheumatic involvement. Multiple small and moderate sized pulmonary infarcts were present. The livet-and lungs weie moderately congested.
Micl-oscolpic examination of the heart revealed extensive acute inflammation of the pericat-dium, (fig. 4) Comment. This patient had obviously active, severe, chronic rheumatic heart disease. While the patient was receiving cortisone, the SGO-T was intermittently abnormal with no consistent relationship to the severity of (ougestive heart failure or to the amount of C1lP in the serum.
Case 4 (fig. 5) 10- year-old Negro boy with a history of migratory polyarthritis for two months. His arthritis had been suppressed by aspirin which was discontinued one month prior to this admission.
On the day of admission, October 8, he was noted to have a nasopharyngitis. The throat culture was positive for group A, fl-hemolytic streptococci. He then complained of mild polyarthralgia. On October 11 he developed frank polvarthritis.
There was no clinical evidence of involvement of the heart except for an apical systolic murmur of grade I to II intensity considered to be of questionable significance. No diastolic murmurs were heard. The erythrocvte sedimentation rate was 42 mm. in 1 hour and the C-reactive protein, 8 The patient cooperated poorly and received his salicvlates irregularly. This was reflected by fluctuating blood salicylate concentrations, falling to as low as 4 mg. per 100 cc. on one occasion. Polyarthralgia reappeared transiently (October 22) and lasted three days. Liver function tests were essentially normal although the cephalin flocculation was 2 plus on one occasion. At no time were the electrocardiogram or cardiac silhouette on x-ray films abnormal. The only suggestive clinical evidence of acute carditis was a slight alteration in the apical systolic murmur which assumed a somewhat harsher quality of grade II to III intensity for one week in December. The C-reactive protein was intermittently positive after the arthritis had disappeared.
Three marked peaks of serum transaminase elevation were observed, the first closely following the attack of polyarthritis, the second and third after the patient had long been completely asymptomatic except for a mild upper respiratory infection. The glutamic oxalacetic transaminase was normal on admission when the temperature, sedimentation Iate and C-reactive protein were markedly abnormal. When the temperature, sedimentation rate and C-reactive protein had returned to normal, the serum level of the enzyme rose to 200 units. At the time of the second peak of the seruum transaminase, the temperature, sedimentation rate and C-reactive protein were again normal. Microscopic evidence of myocardial hypertrophy was present in all cases; 27 sera were analyzed of which 12 were abnormal.
This table analyzes the correlation of the serum glutamic oxalacetic transaminase with the microscopic findings in autopsy and atrial biopsy material.
During the period of the third elevation of the serum transaminase, the C-reactive protein rose to 5 mm. and the sedimentation rate to 28 mm. in 1 hour.
Cortisone was administered in a dose of 300 mg. on October 26 in an attempt to determine its effect on the serum concentration of the glutamic oxalacetic transaminase. However, the results of the experiment could not be interpreted because the control serum obtained immediately prior to therapy but analyzed the next day, showed that the concentration of the enzyme in the serum had already returned to normal.
Comment. This case of frank polyarthritis is of particular interest in that it is the only case in this series in which the transaminase of the serum was repeatedly abnormal despite the absence of previously known rheumatic heart disease or definite evidence of clinical cardiac involvement. There was, however, a transient change in the quality and intensity of the apical systolic murmur and there was laboratory evidence of persistent inflammation as manifested by the intermittently positive C-reactive protein. Polyarthritis, per se, did not seem to be related to the elevations of the serum glutamic oxalacetic transaminase, since the second and third peaks of enzyme concentration occurred when no polyarthritis was present.
One patient with known rheumatic heart disease showed an elevated transaminase level of 70 units on one occasion during the course of virus pneumonia. At this time, his electrocardiogram showed abnormal T-waves which reverted to normal with the subsidence of the pneumonia. We believe it is likely that this patient had the mild myocarditis occasionally seen during virus infections. 17 
Correlation with Microscopic Findings
Sections of the heart were available for microscopic study in 15 patients (table 2) . This material consisted of biopsies of atrial appendages obtained at the time of mitral valulotomy in 12 patients and autopsy material in 3 patients. Only one of the patients (C. M., fig. 2 The question of whether steroid or salicylate therapy may influence the serumi level of glutamic oxalacetic transaminase is of (coi1-siderabl e theoretic and practical importanice. At present, the index of "adequate" antirheumatic therapy is considered to be suppression of laboratory evidence of inflammation as well as a satisfactory clinical response. However, the ultimate goal in treating rheumatic fever is protection of the patient against permanent cardiac injury. If the (oneeltiationi of transaminase in the serum is anr index of myocardial fiber injury, as suggeste(1 above, it is possible that an attempt should be made to increase or (onlltiniue anitir'heuiatic( therapy until the serum transaminase returns to normal levels.
The normal transaminase concentrations in the spinal fluid in the three paltielents vith chorea who were stuldiedl are not surprising in view of the alsence of (ihaniges ini the cerebrospinal fluid in chorea ustually asXsociate(l with inflammatory (disease.2" The miost (OIImOI microscopic finidinig in thei braini is perivats(ular infiltration with roun(l cells. No necrosis of brain tissue is seen, hence a release of transaminase would not be expected.
In a total of six rheumiatic fever la)tients, simultaneous measurements of transtaminase in the spinal fluid and 1lood were, performed. The ratio of serumi concentration to spinal fluid concentration ranged from 2:1 to 3:1, indicating that a barrier to free diffusion of transaminase is present at the sumbarachnoil membrane.
Serum glutamnic oxalacetic transainimmase (SGO-T) was studied in 64 patients in various stages of rheumatic fever and in 15 patients, either at autopsy or in whom atrial biopsy was performed during mitral comimissurotomy.
Elevations in the level of this serum enzyme occurred whvth greatest frequency in. patients with clinical or histologic evidence of active rheumatic carditis. Normal values were found in rhetumatic patienrts without clinical evidence of active cardiac involvement. The serum level was within normal limits in all patients after the acute rheumatic process subsided.
Although frequently high, the levels of serumi gli-tamiic oxalace tic transaminase were 1)ot consis-tently elevated in patients with active carditis and did not follow the clinical course of -i he disease closely.
The effect of aspirin or cortisotne upon the concentration of transaminase in the serum could not be evaluated clearly in the absence of a control group. Some patients with severe, protract(ed carditis continued to have an elevated serum level of glutainic oxalacetic transamninase despite the prolonged administration of relatively large doses of cortisone.
The probable relationship of increased transaminase activity to myocardial damage in rheumatic carditis is discussed.
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